A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics
Phase of Trial: Phase IV
Latest Information Update: 03 Jan 2019
At a glance
- Drugs Infliximab (Primary) ; Ustekinumab (Primary) ; Acitretin; Adalimumab; Antipsoriatics; Ciclosporin; Etanercept; Methotrexate; Psoralens
- Indications Plaque psoriasis; Psoriasis; Psoriatic arthritis
- Focus Adverse reactions
- Acronyms PSOLAR
- Sponsors Janssen Biotech
- 27 Dec 2018 Planned End Date changed from 30 Sep 2029 to 1 Dec 2029.
- 28 Nov 2018 Planned number of patients changed from 12000 to 16000.
- 28 Nov 2018 Planned End Date changed from 31 May 2021 to 30 Sep 2029.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History